Qarziba Dinutuximab Beta for Neuroblastoma Apple Globalcare

Qarziba contains dinutuximab beta, an immunotherapy for high-risk neuroblastoma. It targets GD2 antigens on tumor cells, activating immune-mediated destruction. Used in combination regimens, it improves survival rates and supports comprehensive cancer treatment strategies.

Strength: 4.5mg

Pack Size: 1s

Storage: 2°C to 8°C

Form: Injection

+91 900 500 9556

Global Shipping : Reliable Global Distribution Network

Express Delivery : Priority Shipping for Every Order

Secure Payments : Trusted Payment Protection System

Disclaimer

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the 'Manufacturer/ TM Owner' section in compliance with statutory requirements. Read More